Community trust must be earned through sustained presence and engagement beyond traditional settings. That is why earlier this month we extended our reach beyond the ASCO Annual Meeting conference halls and into the local Chicago community itself – catalyzing discussions and actions to address healthcare inequities where they will have the greatest impact. Over the course of the weekend, we connected with and inspired students at Chicago Collegiate Charter School to pursue careers in STEM, sponsored a health equity symposium in partnership with the American Cancer Society and The University of Illinois Cancer Center, convened patient advocates and LGBTQ+ community leaders and sparked conversations challenging ASCO attendees to ask bigger questions about health outcome disparities across zip codes. Learn more about our community-centered approach at the world’s largest cancer research conference: http://spr.ly/6044gYhd0 #ASCO24
Genentech’s Post
More Relevant Posts
-
Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7
-
We are continuously researching and developing treatment approaches that push past current boundaries for retinal conditions. Our recent innovations are a testament to our commitment to helping the retina community address conditions that cause blindness. Learn more about our innovations for wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion: http://spr.ly/60499Ymr1
-
Congratulations to our own Aviv Regev, Head of Genentech Research and Early Development, for being elected both as The Royal Society (UK) Foreign Member and an EMBO Associate Member this year. Both of these recognitions honor scientists who have made outstanding contributions to science and are leaders in their fields.
-
-
Today, we reintroduced a first-of-its-kind therapeutic approach that provides an alternative to standard of care eye injections for wet age-related macular degeneration, a leading cause of blindness for people aged 60 and over in the U.S. This evolution of the Port Delivery Platform lays the foundation for future retinal advancements. Read the full announcement here: http://spr.ly/60449Y8DE
Genentech: Press Releases | Monday, Jul 8, 2024
gene.com
-
The FDA approved the prefilled syringe version of our medicine to treat wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Together, these three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss. The prefilled syringe is designed to provide retina specialists a ready-to-use option for simpler administration. Learn more: http://spr.ly/60489pado
Genentech: Press Releases | Thursday, Jul 4, 2024
gene.com
-
We had another amazing year celebrating the LGBTQ+ community at the San Francisco Pride Parade! This weekend, hundreds of our employees, led by our employee resource group gPRIDE, came together to connect, spread joy and uplift LGBTQ+ people within our community and beyond. Check out some of our favorite moments from the parade and our float. #PrideMonth #SFPRIDE54
-
-
In S5E04 of our podcast, Two Scientists Walk Into A Bar, antibody engineers Yan Wu and Paul Carter discuss initial obstacles they've faced in this challenging field, antibody engineering advances they're excited about, and how computational methods like AI will continue transforming antibody discovery and development. Listen to the full episode: http://spr.ly/6042gmjk4
Engineering Therapeutic Antibodies
-
A new episode of our podcast, Two Scientists Walk Into A Bar just dropped! Antibody engineers Yan Wu and Paul Carter join us to discuss all things antibodies – from initial obstacles in developing antibody therapies, to advances in antibody engineering that are creating new classes of medicines. Plus, they share their thoughts on how #ArtificialIntelligence and #MachineLearning will be game changers for optimizing antibody design and generating new therapeutic antibodies from scratch. Listen to the full episode here: http://spr.ly/6047gmjD9
Engineering Therapeutic Antibodies
